Review of a New Antimetabolic Agent 1-Hexylcarbamoyl-5-Fluorouracil (HCFU)
- 1 January 1980
- book chapter
- Published by Springer Nature
- Vol. 70, 125-132
- https://doi.org/10.1007/978-3-642-81392-4_13
Abstract
A new 5-fluorouracil (5-FU) derivative, l-hexylcarbamoyl-5-fluorouracil (HCFU), has been developed in the National Cancer Center, and its phase I study is being performed in Japan by a clinical study group involving major institutions. Its LD50 values are nearly equal to those of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) and greater than those of 5-FU, and this compound is more effective than the latter two analogues against various experimental murine tumor systems. In the phase I study, the incidence ratio of side effects was dose dependent, and the characteristic subjective symptoms were hot sensation and pollakisuria. No hematologic or serum biochemical changes were noted.Keywords
This publication has 3 references indexed in Scilit:
- Antitumor activity of 1-acyloxymethyl derivatives of 5-fluorouracil against L1210 leukemia.Journal of Pharmacobio-Dynamics, 1982
- Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in Lewis lung carcinoma and B16 melanoma.Journal of Pharmacobio-Dynamics, 1978
- 5-Fluorouracil Derivatives. I. The Synthesis of 1-Carbamoyl-5-fluorouracilsBulletin of the Chemical Society of Japan, 1977